9MW2921 / Mabwell (Shanghai) Biosci - LARVOL DELTA

A first-in-human clinical study of 9MW2921, a novel TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumors. (ASCO 2025) - P1/2 | "The data indicated that 9MW2921 has acceptable tolerability and promising anti-tumor activity in patients with advanced EC, HR+/HER2- BC, HER2- GC and nsq-NSCLC."

Clinical • Metastases • P1 data • Anemia • Breast Cancer • Dental Disorders • Endometrial Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Stomatitis • HER-2

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=261 | Active, not recruiting | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Oncology • Solid Tumor

Mabwell to Present ADC Platform IDDC and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London (PRNewswire) - "Mabwell...announced that it will present its next generation ADC platform IDDC and the latest study results of multiple novel ADCs (9MW2821, 7MW3711, 9MW2921) developed based on this platform as poster presentation at the 14th World ADC London from March 12-15, 2024 local time."

Clinical data • Esophageal Cancer • Gynecologic Cancers • Oncology • Solid Tumor

ADC clinical progress | Maiwei Biotechnology completed the first patient administration of two innovative ADC drugs [Google translation] (eBiotrade.com) - "Maiwei Biotech...announced its independently developed innovative drug targeting Trop-2 ADC (R&D The first patient has recently been dosed with the innovative drug targeting B7-H3 ADC (codename: 9MW2921) (codename: 7MW3711)."

Trial status • Oncology • Solid Tumor

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=261 | Recruiting | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=261 | Not yet recruiting | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND (PRNewswire) - "Mabwell...announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical Products Administration (NMPA). 9MW2921 is developed by Mabwell's novel antibody-drug conjugate plateform IDDC™."

New trial • Oncology • Solid Tumor